SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
10x Genomics, Inc. (TXG) has a negative trailing P/E of -65.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -1.52%.
Criteria proven by this page:
- VALUE (29/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -65.8); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -1.52%); analyst consensus target implies downside from the current price ($21.00, 15.3%).
- Trailing Earnings Yield -1.52% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $21.00 (-15.3% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
29/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TXG
Valuation Multiples
P/E (TTM)-65.8
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio3.60
P/S Ratio4.48
EV/EBITDA-204.6
Per Share Data
EPS (TTM)$-0.34
Book Value / Share$6.27
Revenue / Share$5.06
FCF / Share$1.02
Yields & Fair Value
Earnings Yield-1.52%
Dividend Yield0.00%
SharesGrow IV$862.61 (+3378.3%)
Analyst Target$21.00 (-15.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2017 |
-32.6 |
0.00 |
-5.43 |
8.60 |
- |
| 2018 |
-6.3 |
-0.02 |
-3.21 |
4.83 |
- |
| 2019 |
-95.3 |
1.05 |
7.09 |
12.11 |
- |
| 2020 |
-26.4 |
-0.05 |
19.38 |
47.93 |
- |
| 2021 |
-282.3 |
3.13 |
20.11 |
33.51 |
- |
| 2022 |
-25.0 |
-0.14 |
5.15 |
8.03 |
- |
| 2023 |
-25.7 |
-0.52 |
8.85 |
10.60 |
- |
| 2024 |
-9.5 |
0.31 |
2.44 |
2.83 |
- |
| 2025 |
-46.7 |
0.61 |
2.56 |
3.17 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-1.62 |
$71.09M |
$-18.76M |
-26.4% |
| 2018 |
$-8.40 |
$146.31M |
$-112.49M |
-76.9% |
| 2019 |
$-0.80 |
$245.89M |
$-31.25M |
-12.7% |
| 2020 |
$-5.37 |
$298.85M |
$-542.73M |
-181.6% |
| 2021 |
$-0.53 |
$490.49M |
$-58.22M |
-11.9% |
| 2022 |
$-1.46 |
$516.41M |
$-166M |
-32.1% |
| 2023 |
$-2.18 |
$618.73M |
$-255.1M |
-41.2% |
| 2024 |
$-1.52 |
$610.79M |
$-182.63M |
-29.9% |
| 2025 |
$-0.35 |
$642.82M |
$-43.54M |
-6.8% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.83 |
$-1.38 – $-0.09 |
$612.59M |
$607.85M – $618.09M |
8 |
| 2027 |
$-0.64 |
$-1.26 – $0.49 |
$656.67M |
$635.09M – $670.49M |
8 |
| 2028 |
$-0.51 |
$-0.86 – $-0.07 |
$708.97M |
$706.91M – $711.02M |
10 |
| 2029 |
$-0.37 |
$-0.38 – $-0.36 |
$777.69M |
$760.74M – $795.23M |
4 |
| 2030 |
$-0.36 |
$-0.37 – $-0.35 |
$841.03M |
$822.71M – $860.01M |
4 |
